BIOTECHNOLOGY

EMD up 37% on no news yesterday… MDMA Therapy for First Responders

Next Investors Mar 08, 2024

Yesterday, our biotech investment Emyria (ASX:EMD) was up 37% on no news.

Signs of life in the small cap market

Next Investors Feb 24, 2024

In this week's trading sessions, we noticed many long ignored stocks in our portfolio and on our watchlist were seeing little nibbles of buying.

US Short Report questions Acadia’s safety - NTI’s competing treatment safety results due within 6 weeks

Next Investors Feb 19, 2024

Neurotech International (ASX: NTI) is currently running a Phase I/II clinical trial for Rett Syndrome.

ALA Bolts on New Technology in Cancer Fighting Cell Therapy Platform

Next Investors Jan 30, 2024

Arovella Therapeutics (ASX:ALA) licensed a new technology today that promises to significantly boost the effectiveness of the company’s solid tumour therapy.

NTI autism clinical trial results in next 8 weeks - can it save billions of dollars in NDIS funding needs?

Wise-Owl Jan 24, 2024

Neurotech International (ASX: NTI) is developing an oral drug treatment that is being clinically trialled with children suffering from some of the negative effects of autism.

Investing in Early-Stage Biotechs and the Drill Race is on...

Next Investors Sep 09, 2023

In this Weekender, we look at the high-risk, high-reward landscape of biotech investing, early-stage companies offer outsized returns on successful clinical trials, aligning perfectly with our investment strategy and providing a unique opportunity to contribute to groundbreaking advancements in medical science.

How the mainstream news shapes the macro themes we invest in

Next Investors Jan 28, 2023

In this weekly wrap, we look at the various outlooks presented by the media toward our key investment themes such as; biotechs, resources and technology companies.

Pre-result build up? The “big catalyst” in 2023

Finfeed Sep 02, 2022

Our biotech Investment and 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), has been busy this year working towards its all important Phase 3 trial and first interim results. After our initial entry at 20c in August 2021, our Investment in DXB is currently sitting below that price at 14.5 cents.

New Portfolio Addition: Arovella Therapeutics

Finfeed Feb 18, 2022

Today we are finally announcing a new investment in the Next Investors portfolio. Arovella Therapeutics (ASX:ALA) is a small ASX biotech going after a unique solution to the scourge of cancer - with cutting edge technology licensed from some of the foremost cancer research institutions - and has attracted big names to the project.

Biotechnology